<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847886</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol LX3305.1-104-DDI</org_study_id>
    <secondary_id>LX3305.104</secondary_id>
    <secondary_id>LX2931</secondary_id>
    <nct_id>NCT00847886</nct_id>
  </id_info>
  <brief_title>Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of LX3305 on methotrexate (MTX)
      pharmacokinetics and to evaluate the safety and tolerability of LX3305 given over 14 days in
      subjects with stable rheumatoid arthritis that are receiving stable doses of MTX.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methotrexate Maximum Plasma Concentration</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration of Methotrexate</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life of Methotrexate in Plasma</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Methotrexate Excreted in the Urine</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>7-Hydroxymethotrexate (7-OH-MTX) Maximum Plasma Concentration</measure>
    <time_frame>Day 15</time_frame>
    <description>7-OH-MTX is the primary metabolite of methotrexate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration of 7-OH-MTX</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of 7-OH-MTX Excreted in the Urine</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of LX3305 in the Presence of MTX</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration of LX3305 in the Presence of MTX</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of LX3305 in Plasma in the Presence of MTX</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Change From Baseline in Absolute Total Lymphocyte Count at Day 15</measure>
    <time_frame>Day 15</time_frame>
    <description>Baseline was defined as pre-dose on Day 1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>LX3305</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral intake of LX3305 for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LX3305 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo dosing with daily oral intake for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX3305</intervention_name>
    <description>Daily oral intake of LX3305 for 14 days.</description>
    <arm_group_label>LX3305</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX3305 Placebo</intervention_name>
    <description>Matching placebo dosing with daily oral intake for 14 days.</description>
    <arm_group_label>LX3305 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Once weekly stable-dose methotrexate.</description>
    <arm_group_label>LX3305</arm_group_label>
    <arm_group_label>LX3305 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females â‰¥ 18 years old

          -  Must be willing to practice 2 adequate methods of contraception for the duration of
             the study

          -  Rheumatoid arthritis present for at least 3 months; functional class I, II, or III as
             defined by ACR criteria

          -  Treatment with methotrexate (7.5 to 25 mg per week) for at least the last 3 months,
             and currently receiving stable dose methotrexate for at least one month prior to the
             start of the study

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Women who are pregnant or nursing

          -  History of other current inflammatory arthritis

          -  History of opportunistic infection

          -  History of recurrent infections or current infection 2 weeks prior to start of study

          -  Presence of significant, uncontrolled medical problems

          -  Treatment with any disease-modifying anti-rheumatoid drugs other than methotrexate
             within 4 weeks prior to start of study

          -  Use of chondroitin sulfate, glucosamine sulfate, minocycline, or matrix
             metalloproteinase inhibitors, H-2 blockers, proton pump inhibitors, or misoprostol
             within 4 weeks prior to study start

          -  Receipt of live vaccine within 8 weeks prior to study start

          -  Rheumatoid arthritis, functional class IV as defined by ACR criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip M. Brown, MD, JD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <results_first_submitted>April 19, 2010</results_first_submitted>
  <results_first_submitted_qc>June 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2010</results_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Joel P. Freiman, MD, MPH (Medical Director, Drug Safety)</name_title>
    <organization>Lexicon Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was performed at one center in Dallas, TX. Recruitment began in January 2009 and the last subject completed the study in March 2009.</recruitment_details>
      <pre_assignment_details>One subject did not complete the study due to an adverse event of uveitis on Day 1 and was not dosed with study drug. This subject was not included in any population analyses. Therefore, the participant flow includes 15 subjects, 12 receiving active drug and 3 receiving placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LX3305 + Methotrexate</title>
          <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Methotrexate</title>
          <description>Matching placebo dosing with daily oral intake for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LX3305 + Methotrexate</title>
          <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Methotrexate</title>
          <description>Matching placebo dosing with daily oral intake for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="10.25"/>
                    <measurement group_id="B2" value="58.7" spread="14.74"/>
                    <measurement group_id="B3" value="59.5" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Methotrexate Maximum Plasma Concentration</title>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Maximum Plasma Concentration</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215" spread="71.4"/>
                    <measurement group_id="O2" value="177" spread="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Plasma Concentration of Methotrexate</title>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration of Methotrexate</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.90" upper_limit="2.98"/>
                    <measurement group_id="O2" value="1.25" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life of Methotrexate in Plasma</title>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life of Methotrexate in Plasma</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="0.520"/>
                    <measurement group_id="O2" value="3.80" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Methotrexate Excreted in the Urine</title>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Methotrexate Excreted in the Urine</title>
          <units>Âµg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3861" spread="1720"/>
                    <measurement group_id="O2" value="4022" spread="1218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>7-Hydroxymethotrexate (7-OH-MTX) Maximum Plasma Concentration</title>
        <description>7-OH-MTX is the primary metabolite of methotrexate.</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>7-Hydroxymethotrexate (7-OH-MTX) Maximum Plasma Concentration</title>
          <description>7-OH-MTX is the primary metabolite of methotrexate.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="12.8"/>
                    <measurement group_id="O2" value="25.5" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Plasma Concentration of 7-OH-MTX</title>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration of 7-OH-MTX</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" lower_limit="5.90" upper_limit="11.98"/>
                    <measurement group_id="O2" value="8.00" lower_limit="4.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of 7-OH-MTX Excreted in the Urine</title>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of 7-OH-MTX Excreted in the Urine</title>
          <units>Âµg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285" spread="106"/>
                    <measurement group_id="O2" value="281" spread="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration of LX3305 in the Presence of MTX</title>
        <time_frame>Day 15</time_frame>
        <population>This outcome was not measured in the Methotrexate + LX3305 placebo subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration of LX3305 in the Presence of MTX</title>
          <population>This outcome was not measured in the Methotrexate + LX3305 placebo subjects.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588" spread="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration of LX3305 in the Presence of MTX</title>
        <time_frame>Day 15</time_frame>
        <population>This outcome was not measured in the Methotrexate + LX3305 placebo subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration of LX3305 in the Presence of MTX</title>
          <population>This outcome was not measured in the Methotrexate + LX3305 placebo subjects.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.42" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life of LX3305 in Plasma in the Presence of MTX</title>
        <time_frame>Day 15</time_frame>
        <population>This outcome was not measured in the Methotrexate + LX3305 placebo subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life of LX3305 in Plasma in the Presence of MTX</title>
          <population>This outcome was not measured in the Methotrexate + LX3305 placebo subjects.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.89" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Change From Baseline in Absolute Total Lymphocyte Count at Day 15</title>
        <description>Baseline was defined as pre-dose on Day 1.</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LX3305 + Methotrexate</title>
            <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Matching placebo dosing with daily oral intake for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Change From Baseline in Absolute Total Lymphocyte Count at Day 15</title>
          <description>Baseline was defined as pre-dose on Day 1.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.049" spread="29.1505"/>
                    <measurement group_id="O2" value="-6.152" spread="15.0143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>22 days</time_frame>
      <desc>An adverse event is defined as any noxious, pathological, or unintended change in anatomical, physiological, or metabolic functions as indicated by physical signs or symptoms occurring in any phase of the clinical study whether or not associated with the study medication and whether or not considered related to the study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>LX3305 + Methotrexate</title>
          <description>Daily oral intake of 100 mg LX3305 for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Methotrexate</title>
          <description>Matching placebo dosing with daily oral intake for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ocular hyperemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea hemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor requires that written permission be given before the investigator can release any data publicly.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joel P. Freiman, MD, MPH - Medical Director, Drug Safety</name_or_title>
      <organization>Lexicon Pharmaceuticals, Inc.</organization>
      <phone>281-863-3000</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

